Cargando…

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience

BACKGROUND: The repeated waves of the COVID-19 pandemic have highlighted the necessity to optimize vaccine responses in immunocompromised populations. We investigated the safety and immunogenicity of a third, booster, dose of the Pfizer BNT162b2 vaccine in heart transplant (HT) patients. METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peled, Yael, Ram, Eilon, Lavee, Jacob, Segev, Amit, Matezki, Shlomi, Wieder-Finesod, Anat, Halperin, Rebecca, Mandelboim, Michal, Indenbaum, Victoria, Levy, Itzchak, Sternik, Leonid, Raanani, Ehud, Afek, Arnon, Kreiss, Yitshak, Lustig, Yaniv, Rahav, Galia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society for Heart and Lung Transplantation. 2022
Materias:	Original Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397500/ https://www.ncbi.nlm.nih.gov/pubmed/34565682 http://dx.doi.org/10.1016/j.healun.2021.08.010

Ejemplares similares

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
por: Peled, Yael, et al.
Publicado: (2021)

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant
por: Peled, Yael, et al.
Publicado: (2022)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
por: Levy, Itzchak, et al.
Publicado: (2022)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study
por: Rahav, Galia, et al.
Publicado: (2021)

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
por: Levy, Itzchak, et al.
Publicado: (2021)

Surgical treatment on infective endocarditis: impact of diabetes on mortality
por: Kogan, Alexander, et al.
Publicado: (2022)

A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

(6) BNT162b2-Vaccine-Induced Neutralization Responses are Immune Correlates of Clinical Protection Against SARS-CoV-2 in Heart Transplant Recipients
por: Peled, Y., et al.
Publicado: (2023)

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
por: Regev-Yochay, Gili, et al.
Publicado: (2021)

BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients
por: Hod, Tammy, et al.
Publicado: (2022)

Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
por: Gilboa, Mayan, et al.
Publicado: (2022)

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2023)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
por: Amit, Sharon, et al.
Publicado: (2021)

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - Implications for the omicron variant: Correspondence
por: Peled, Yael, et al.
Publicado: (2022)

Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study
por: Shmueli, Einat S., et al.
Publicado: (2021)

Fifth bivalent omicron BA.4/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipients
por: Peled, Yael, et al.
Publicado: (2023)

(7) Cellular and Humoral Responses to Vaccination Before or after SARS-CoV-2 Infection - Bridging the Knowledge Gap to End the Pandemic for Heart Transplant Recipients
por: Peled, Y., et al.
Publicado: (2023)

(8) 5th Dose Bivalent Omicron-Containing Booster Vaccine Against Covid-19 in Heart Transplant Recipients
por: Peled, Y., et al.
Publicado: (2023)

Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study
por: Shacham-Shmueli, Einat, et al.
Publicado: (2022)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2022)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers
por: Lustig, Yaniv, et al.
Publicado: (2021)

Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2023)

Buying Time with COVID-19 Outbreak Response, Israel
por: Leshem, Eyal, et al.
Publicado: (2020)

Humoral Immunity of Unvaccinated COVID-19 Recovered vs. Naïve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study
por: Joseph, Gili, et al.
Publicado: (2023)

Complicated Pocket Infection in Patients Undergoing Lead Extraction: Characteristics and Outcomes
por: Milman, Anat, et al.
Publicado: (2023)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Candida auris Infection Leading to Nosocomial Transmission, Israel, 2017
por: Belkin, Ana, et al.
Publicado: (2018)

Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours
por: Margalit, Ofer, et al.
Publicado: (2022)

Missed opportunities for earlier diagnosis of HIV in patients who presented with advanced HIV disease: a retrospective cohort study
por: Levy, Itzchak, et al.
Publicado: (2016)

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up
por: Barda, Noam, et al.
Publicado: (2023)

Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients
por: Shmueli, Einat Shacham, et al.
Publicado: (2022)

Improved long-term outcomes after heart transplantation utilizing donors with a traumatic mode of brain death
por: Ram, Eilon, et al.
Publicado: (2019)

The predictive value of five glomerular filtration rate formulas for long‐term mortality in patients undergoing coronary artery bypass grafting
por: Ram, Eilon, et al.
Publicado: (2022)

Revascularization outcomes in diabetic patients presenting with acute coronary syndrome with non-ST elevation
por: Ram, Eilon, et al.
Publicado: (2022)

COVID-19 vaccine efficacy data: solid enough to delay second dose? – Authors' reply
por: Amit, Sharon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mnkcssj9lg3n2nf7s79a7kgrgj